Sanofi nabs pri­or­i­ty re­view for he­mo­phil­ia A pro­gram as phar­ma awaits FDA de­ci­sion

Sanofi has been set­ting it­self up for a re­match against oth­er phar­mas in the he­mo­phil­ia space, and thanks to the FDA, the com­pa­ny is now one step clos­er.

The French phar­ma gi­ant put out word Tues­day that the FDA has giv­en pri­or­i­ty re­view to Sanofi’s efane­soc­tocog al­fa (BIVV001) for he­mo­phil­ia A. The drug can­di­date, which Sanofi has been col­lab­o­rat­ing on with So­bi, is be­ing re­viewed with a tar­get date of Feb­ru­ary 28, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER